Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.62 |
| ▸ | MAOB | P27338 | 3/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.62 |
| ▸ | SDHA | P31040 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CALML3 | P27482 | 1/20 | 0.62 |
| ▸ | F10 | P00742 | 11/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28594529 | 1.00 | MAOA (0.62) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL27875818 | 0.90 | MAOA (0.61) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL483916 | 0.90 | MAOA (0.61) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL27707418 | 0.90 | MAOA (0.61) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL28594531 | 0.86 | MAOA (0.55) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL7537310 | 0.86 | MAOA (0.55) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL7083563 | 0.86 | MAOA (0.55) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL5431183 | 0.85 | MAOB (0.75) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL27801854 | 0.85 | MAOB (0.75) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL5636250 | 0.83 | F10 (0.77) | F10ABCB11F2ST14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020095054-A1 | Process to produce oxazolidinones | PHARMACIA & UPJOHN COMPANY | 2002-07-18 | — | — | US | claimed |
| CN-104513211-B | A kind of method preparing linezolid | 丹阳恒安化学科技研究所有限公司 | 2017-01-04 | — | — | CN | disclosed |
| CN-104262280-B | A kind of preparation method of linezolid | 山东华生化学股份有限公司 | 2016-07-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020095054-A1 | Process to produce oxazolidinones | ADH1A, ADH5, ADH1C | MAOA 156/4885MAOB 189/4885PTGS1 2552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.